Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910128 | 0.94 | PPARG (0.75) | PPARGPPARA | |
| SCHEMBL30515143 | 0.91 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL15267315 | 0.91 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL3808617 | 0.91 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL9910077 | 0.91 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL13063616 | 0.90 | PPARG (0.75) | PPARGPPARA | |
| SCHEMBL20235152 | 0.88 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL20222425 | 0.88 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL20222424 | 0.88 | PPARG (0.71) | PPARGPPARA | |
| SCHEMBL9909865 | 0.87 | PPARG (0.69) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025054309-A1 | METHODS OF IDENTIFYING AND TREATING PATIENTS HAVING NEURODEGENERATIVE DISEASE BASED ON PLASMA BIOMARKER LEVELS | T3D THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025024308-A1 | METHODS OF TREATING ENDOTHELIAL CELL AND AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | ACAT2, ACAT1, CPT1A | PPARG 14/4885PPARA 12/4885 |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885 |
| US-20180200230-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885 |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885 |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | MAPT, APP, IAPP | PPARG 2905/4885PPARA 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.